{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:13:50Z","timestamp":1781630030349,"version":"3.54.5"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>The use of nondihydropyridine calcium channel blockers (NDCCBs) to achieve rate control in atrial fibrillation with the rapid ventricular rate (AF RVR) is not recommended in patients with comorbid heart failure with reduced ejection fraction (HFrEF) due to the concern for further blunting of contractility. However, these recommendations are extrapolated from data examining chronic NDCCB use in HFrEF patients, and comorbid AF was not analyzed. These recommendations also do not cite the hemodynamic effects or clinical outcomes of NDCCBs for acute rate control in HFrEF patients with AF RVR. It is our goal to open the discussion concerning the hemodynamic effects and safety profile of NDCCBs for acute rate control in this specific patient population. In the acute setting of AF RVR and HFrEF, there is a paucity of low-quality data on the safety and hemodynamic effects of NDCCBs, with mixed results. There has not been a clear signal toward adverse outcomes with NDCCBs, particularly for diltiazem. Data in this scenario is similarly limited for beta blockers, which provide the additional hemodynamic effect of the neurohormonal blockade, which provides a long-term mortality benefit to HFrEF patients. We support the cautious use of beta blockers as first-line therapy in clinical settings where an acute rate control strategy for AF RVR is warranted. We also support diltiazem as a reasonable second-line option, though the relative paucity of data calls for further research to validate this conclusion. Verapamil in this setting should be avoided until more data are available.<\/jats:p>","DOI":"10.1097\/crd.0000000000000585","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T13:08:21Z","timestamp":1691413701000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Nondihydropyridine Calcium Channel Blockers for Acute Rate Control in Atrial Fibrillation with Rapid Ventricular Response and Comorbid Heart Failure with Reduced Ejection Fraction"],"prefix":"10.1097","volume":"33","author":[{"given":"Paul C.","family":"Montana","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Miami Miller School of Medicine\/Jackson Memorial Hospital, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Miami Miller School of Medicine\/Jackson Memorial Hospital, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Dyal","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL"},{"name":"Cardiovascular Division, Miami VA Healthcare System, Miami, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Goldberger","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, University of Miami, Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,8,7]]},"reference":[{"key":"R1-20250203","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation.","volume":"64","author":"January","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"R2-20250203","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1136\/emj.2003.012047","article-title":"Comparison of the effectiveness of intravenous diltiazem and metoprolol in the management of rapid ventricular rate in atrial fibrillation.","volume":"22","author":"Dermircan","year":"2005","journal-title":"Emerg Med J"},{"key":"R3-20250203","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1573403X15666190618110941","article-title":"Digoxin in atrial fibrillation: an old topic revisited.","volume":"16","author":"Ferrari","year":"2020","journal-title":"Curr Cardiol Rev"},{"key":"R4-20250203","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.hrthm.2007.07.020","article-title":"A practical guide for clinicians who treat patients with amiodarone: 2007.","volume":"4","author":"Goldschlager","year":"2007","journal-title":"Heart Rhythm"},{"key":"R6-20250203","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00003246-200106000-00011","article-title":"Amiodarone versus diltiazem for rate control in critically ill patients with atrial tachyarrhythmias.","volume":"29","author":"Delle Karth","year":"2001","journal-title":"Crit Care Med"},{"key":"R7-20250203","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1097\/CCM.0b013e3181a02f56","article-title":"Intravenous diltiazem is superior to intravenous amiodarone or digoxin for achieving ventricular rate control in patients with acute uncomplicated atrial fibrillation.","volume":"37","author":"Siu","year":"2009","journal-title":"Crit Care Med"},{"key":"R8-20250203","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/SHK.0000000000000869","article-title":"Management of atrial fibrillation with rapid ventricular response in the intensive care unit: a secondary analysis of electronic health record data.","volume":"48","author":"Moskowitz","year":"2017","journal-title":"Shock"},{"key":"R9-20250203","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1097\/CCM.0b013e3181709e43","article-title":"Treatment of new-onset atrial fibrillation in noncardiac intensive care unit patients: a systematic review of randomized control trials.","volume":"36","author":"Kanji","year":"2008","journal-title":"Crit Care Med"},{"key":"R10-20250203","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/cc6136","article-title":"Clinical review: treatment of new-onset atrial fibrillation in medical intensive care patients--a clinical framework.","volume":"11","author":"Sleeswijk","year":"2007","journal-title":"Crit Care"},{"key":"R11-20250203","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40560-015-0085-4","article-title":"Epidemiology, prevention, and treatment of new-onset atrial fibrillation in critically ill: a systematic review.","volume":"3","author":"Yoshida","year":"2015","journal-title":"J Intensive Care"},{"key":"R12-20250203","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-8703(98)70217-0","article-title":"Cardiac performance early after cardioversion from atrial fibrillation.","volume":"136","author":"Raymond","year":"1998","journal-title":"Am Heart J"},{"key":"R13-20250203","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0002-9149(01)01699-X","article-title":"Effect of cardioversion of atrial fibrillation on improvement in left ventricular performance.","volume":"88","author":"Viswanathan","year":"2001","journal-title":"Am J Cardiol"},{"key":"R14-20250203","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.CIR.0000108928.25690.94","article-title":"Effects of carvedilol on left ventricular remodeling after acute myocardial infarction.","volume":"109","author":"Doughty","year":"2004","journal-title":"Circulation"},{"key":"R15-20250203","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1056\/NEJM198808183190701","article-title":"The effect of diltiazem on mortality and reinfarction after myocardial infarction.","volume":"319","year":"1988","journal-title":"N Engl J Med"},{"key":"R16-20250203","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1161\/01.CIR.83.1.52","article-title":"Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. the adverse experience committee; and the multicenter diltiazem postinfarction research group.","volume":"83","author":"Goldstein","year":"1991","journal-title":"Circulation"},{"key":"R17-20250203","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction \u2014 results of the survival and ventricular enlargement trial.","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"R18-20250203","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0002-8703(98)70315-1","article-title":"Absence of a deleterious effect of calcium channel blockers in patients with left ventricular dysfunction after myocardial infarction: the SAVE study experience. SAVE investigators. survival and ventricular enlargement.","volume":"135","author":"Hager","year":"1998","journal-title":"Am Heart J"},{"key":"R19-20250203","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/0735-1097(89)90607-4","article-title":"Beneficial effects of long-term diltiazem treatment in dilated cardiomyopathy.","volume":"13","author":"Figulla","year":"1989","journal-title":"J Am Coll Cardiol"},{"key":"R20-20250203","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0002-8703(97)70150-9","article-title":"Association of calcium channel blocker use with increased rate of acute myocardial infarction in patients with left ventricular dysfunction.","volume":"133","author":"Kostis","year":"1997","journal-title":"Am Heart J"},{"key":"R21-20250203","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1161\/01.CIR.94.3.346","article-title":"Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. results of the diltiazem in dilated cardiomyopathy trial.","volume":"94","author":"Figulla","year":"1996","journal-title":"Circulation"},{"key":"R22-20250203","first-page":"778","article-title":"The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II--DAVIT II).","volume":"66","year":"1990","journal-title":"Am J Cardiol"},{"key":"R23-20250203","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0022-3565(25)33108-3","article-title":"Inotropic and chronotropic effects of vasodilators.","volume":"221","author":"P\u00e9rez","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"R24-20250203","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0002-9149(84)80199-X","article-title":"Hemodynamic effects of intravenous diltiazem with impaired left ventricular function.","volume":"54","author":"Materne","year":"1984","journal-title":"Am J Cardiol"},{"key":"R25-20250203","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0735-1097(84)80365-4","article-title":"Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure.","volume":"3","author":"Walsh","year":"1984","journal-title":"J Am Coll Cardiol"},{"key":"R26-20250203","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/0002-9149(87)90862-9","article-title":"Central and renal hemodynamic effects and hormonal response to diltiazem in severe congestive heart failure.","volume":"59","author":"Kulick","year":"1987","journal-title":"Am J Cardiol"},{"key":"R27-20250203","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/0002-9149(83)90309-0","article-title":"Hemodynamic and myocardial performance characteristics after verapamil use in congestive heart failure.","volume":"51","author":"Ferlinz","year":"1983","journal-title":"Am J Cardiol"},{"key":"R28-20250203","first-page":"107","article-title":"Safety of calcium-channel blockers during radial cardiac catheterization in patients with acute myocardial infarction or systolic heart failure.","volume":"31","author":"Lawson","year":"2019","journal-title":"J Invasive Cardiol"},{"key":"R29-20250203","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/j.1875-9114.1997.tb03087.x","article-title":"Comparison of intravenous diltiazem and verapamil for the acute treatment of atrial fibrillation and atrial flutter.","volume":"17","author":"Phillips","year":"1997","journal-title":"Pharmacotherapy"},{"key":"R30-20250203","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajem.2022.03.058","article-title":"Acute management of atrial fibrillation in congestive heart failure with reduced ejection fraction in the emergency department.","volume":"58","author":"Hasbrouck","year":"2022","journal-title":"Am J Emerg Med"},{"key":"R31-20250203","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40261-018-0631-7","article-title":"Safety of intravenous diltiazem in reduced ejection fraction heart failure with rapid atrial fibrillation.","volume":"38","author":"Jandali","year":"2018","journal-title":"Clin Drug Investig"},{"key":"R32-20250203","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/0002-9149(94)90580-0","article-title":"Intravenous diltiazem for the treatment of patients with atrial fibrillation or flutter and moderate to severe congestive heart failure.","volume":"74","author":"Goldenberg","year":"1994","journal-title":"Am J Cardiol"},{"key":"R33-20250203","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ajem.2018.04.062","article-title":"Metoprolol vs. diltiazem in the acute management of atrial fibrillation in patients with heart failure with reduced ejection fraction.","volume":"37","author":"Hischy","year":"2019","journal-title":"Am J Emerg Med"},{"key":"R34-20250203","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/BF00051125","article-title":"Usefulness of diltiazem in the acute management of supraventricular tachyarrhythmias in the elderly.","volume":"10","author":"Millaire","year":"1996","journal-title":"Cardiovasc Drugs Ther"},{"key":"R35-20250203","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/0002-9149(91)90885-O","article-title":"Effects of intravenous diltiazem on rapid atrial fibrillation accompanied by congestive heart failure.","volume":"67","author":"Heywood","year":"1991","journal-title":"Am J Cardiol"},{"key":"R36-20250203","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1161\/CIRCULATIONAHA.114.013709","article-title":"Rate-control treatment and mortality in atrial fibrillation.","volume":"132","author":"Chao","year":"2015","journal-title":"Circulation"},{"key":"R37-20250203","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(05)67661-1","article-title":"Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.","volume":"366","author":"Chen","year":"2005","journal-title":"Lancet"},{"key":"R38-20250203","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jchf.2015.03.008","article-title":"Effects of beta-blocker withdrawal in acute decompensated heart failure: a systematic review and meta-analysis.","volume":"3","author":"Prins","year":"2015","journal-title":"JACC Heart Fail"},{"key":"R39-20250203","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13054-021-03706-2","article-title":"Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.","volume":"25","author":"Di Santo","year":"2021","journal-title":"Crit Care"},{"key":"R40-20250203","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1161\/01.CIR.94.3.340","article-title":"Negative chronotropic effect of \u03b2-blockade therapy reduces myocardial oxygen expenditure for nonmechanical work.","volume":"94","author":"Yamakawa","year":"1996","journal-title":"Circulation"},{"key":"R41-20250203","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ajem.2021.08.082","article-title":"Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: a meta-analysis.","volume":"51","author":"Lan","year":"2022","journal-title":"Am J Emerg Med"},{"key":"R42-20250203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/0002-9149(89)90141-0","article-title":"Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter.","volume":"63","author":"Platia","year":"1989","journal-title":"Am J Cardiol"},{"key":"R43-20250203","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1016\/j.jacc.2017.04.001","article-title":"Heart rate and rhythm and the benefit of beta blockers in patients with heart failure.","volume":"69","author":"Kotecha","year":"2017","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T19:02:32Z","timestamp":1738609352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,7]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000585","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,7]]}}}